Prostate Cancer Clinical Trials

286 studies are recruiting for prostate cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

   To learn about the effectiveness of adding talazoparib to the standard of care treatment combination of androgen ablation therapy (hormone therapy, also known as ADT) and enzalutamide in patients with prostate cancer that has spread into the lymph nodes.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05873192 on ClinicalTrials.gov

2. Evaluating Tolerability of ePUHRT With Brachytherapy Boost

   The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of inter…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Run by

   Indiana University

   See if you can join NCT06817668 on ClinicalTrials.gov

3. Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

   The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on active surveillance.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Desai Sethi Urology Institute, Miami, Florida

   Locations

   2 in total

   Run by

   University of Miami

   See if you can join NCT07278362 on ClinicalTrials.gov

4. A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

   This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of [225Ac]Ac-AKY-2519 in participants with metastatic castration-resistant pro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Hoag Memorial Hospital Presbyterian, Irvine, California

   Locations

   8 in total

   Run by

   Aktis Oncology, Inc.

   See if you can join NCT07581184 on ClinicalTrials.gov

5. Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

   Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States. Survival rates for these cancers are lower than 50% if they spread to othe…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07667400 on ClinicalTrials.gov

6. Autonomic and Renal Contributions to Hypertension With ADT

   This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the us…

   Stage

   Phase 4

   Ages

   40 and older

   Site

   Virginia Commonwealth University, Richmond, Virginia

   Run by

   Virginia Commonwealth University

   See if you can join NCT07848828 on ClinicalTrials.gov

7. A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

   This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of [225Ac]Ac-AKY-2519 in participants with B7-H3 imaging positive soli…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Biogenix Molecular, LLC, Miami, Florida

   Locations

   2 in total

   Run by

   Aktis Oncology, Inc.

   See if you can join NCT07887971 on ClinicalTrials.gov

8. A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

   To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   10 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT05751434 on ClinicalTrials.gov

9. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic in Arizona - Phoenix ( Site 0044), Phoenix, Arizona

   Locations

   303 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

10. Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

    Background: - Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some tumors may be harder to treat with radiation or even with surgery. This happens to a small number of men who have either radiation or surgery f…

    Stage

    Not phased

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT01834001 on ClinicalTrials.gov

11. Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

    Background: Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer. This will help them understand any changes in cells and genes. These changes might lead to the development and progress…

    Stage

    Not phased

    Ages

    18 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT02594202 on ClinicalTrials.gov

12. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage

    Phase 1

    Ages

    18 to 100

    Site

    University of Alabama at Birmingham Hospital, Birmingham, Alabama

    Locations

    38 in total

    Run by

    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

13. Exercise in Prostate Cancer

    The goal of this clinical trial is to learn how exercise intervention affects circulating tumor cells (CTC) in men with advanced prostate cancer. The primary objective is to determine if an exercise intervention decreases CTCs in men with advanced prostate cancer. Participants will have baseline sc…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Johns Hopkins University, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06165302 on ClinicalTrials.gov

14. Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

    This study aims to evaluate the role of PSMA-PET and circulating tumor DNA (ctDNA) in monitoring prostate cancer progression and response to radiotherapy (RT). Specifically, it investigates how often early progression is detected on PSMA-PET before PSA rise, examines PET responses of lesions treate…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT07210086 on ClinicalTrials.gov

15. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 includes dose escalation cohorts evaluating PF-07220060 as sin…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Smilow Cancer Hospital - Yale New Haven Health, New Haven, Connecticut

    Locations

    39 in total

    Run by

    Pfizer

    See if you can join NCT04557449 on ClinicalTrials.gov

16. A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

    The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga …

    Stage

    Not phased

    Ages

    18 and older

    Site

    UC Davis EXPLORER Molecular Imaging Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT05160480 on ClinicalTrials.gov

17. Collection of Blood From Patients With Prostate Cancer

    Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. * Genes contain the hereditary information that is passed down from parents to children. Although ever…

    Stage

    Not phased

    Ages

    18 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT00923221 on ClinicalTrials.gov

18. Precision-Based Genomics in Prostate Cancer

    Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is. Objective: To look at gene m…

    Stage

    Not phased

    Ages

    18 to 120

    Site

    University of California San Diego, La Jolla, California

    Locations

    11 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT04706663 on ClinicalTrials.gov

19. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    96 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

20. Real World Prostate Cancer Registry

    Prostate cancer is the most common cancer diagnosed in men in the USA with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 Prostate cancer is a very heterogeneous disease that has different presentations, molecular and pathological fe…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cincinnati Cancer Advisors, Cincinnati, Ohio

    Run by

    Cincinnati Cancer Advisors

    See if you can join NCT06355336 on ClinicalTrials.gov

21. Exercise-induced Steroid Changes in Active Surveillance for Prostate Cancer

    The purpose of this research study is to understand how a short session of a home-based bodyweight high-intensity interval training (HIIT) affects steroid hormone levels in men on active surveillance for low-grade prostate cancer.

    Stage

    Not phased

    Ages

    18 to 80

    Site

    University of Miami Hospitals and Clinics, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT07518888 on ClinicalTrials.gov

22. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    39 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

23. Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

    This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small number of cells into the bloodstream every day. These are called circulating tumor cells (CTCs). Some…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachsuetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT01961713 on ClinicalTrials.gov

24. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    11 in total

    Run by

    Nammi Therapeutics Inc

    See if you can join NCT06582017 on ClinicalTrials.gov

25. Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

    The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patients with PSMA-positive but conventionally negative pelvic lymphadenopathy (i.e., <1 cm in smallest …

    Stage

    Phase 2

    Ages

    30 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT07237269 on ClinicalTrials.gov